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Studies proved that among all α1-adrenoceptors, cardiac myocytes functionally express
only α1A- and α1B-subtype. Scientists indicated that α1A-subtype blockade might be
beneficial in restoring normal heart rhythm. Therefore, we aimed to determine the role of
α1-adrenoceptors subtypes (i.e., α1A and α1B) in antiarrhythmic effect of six structurally
similar derivatives of 2-methoxyphenylpiperazine. We compared the activity of studied
compounds with carvedilol, which is β1- and α1-adrenoceptors blocker with antioxidant
properties. To evaluate the affinity for adrenergic receptors, we used radioligand
methods. We investigated selectivity at α1-adrenoceptors subtypes using functional
bioassays. We tested antiarrhythmic activity in adrenaline-induced (20µg/kg i.v.), calcium
chloride-induced (140 and 25mg/kg i.v.) and barium chloride-induced (32 and 10mg/kg
i.v.) arrhythmia models in rats. We also evaluated the influence of studied compounds
on blood pressure in rats, as well as lipid peroxidation. All studied compounds
showed high affinity toward α1-adrenoceptors but no affinity for β1 receptors.
Biofunctional studies revealed that the tested compounds blocked α1A-stronger than
α1B-adrenoceptors, but except for HBK-19 they antagonized α1A-adrenoceptor weaker
than α1D-subtype. HBK-19 showed the greatest difference in pA2 values—it blocked
α1A-adrenoceptors around seven-fold stronger than α1B subtype. All compounds
showed prophylactic antiarrhythmic properties in adrenaline-induced arrhythmia, but
only the activity of HBK-16, HBK-17, HBK-18, and HBK-19 (ED50 = 0.18–0.21)
was comparable to that of carvedilol (ED50 = 0.36). All compounds reduced
mortality in adrenaline-induced arrhythmia. HBK-16, HBK-17, HBK-18, and HBK-19
showed therapeutic antiarrhythmic properties in adrenaline-induced arrhythmia. None
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of the compounds showed activity in calcium chloride- or barium chloride-induced
arrhythmias. HBK-16, HBK-17, HBK-18, and HBK-19 decreased heart rhythm at ED84.
All compounds significantly lowered blood pressure in normotensive rats. HBK-18
showed the strongest hypotensive properties (the lowest active dose: 0.01 mg/kg).
HBK-19 was the only compound in the group, which did not show hypotensive effect
at antiarrhythmic doses. HBK-16, HBK-17, HBK-18, HBK-19 showed weak antioxidant
properties. Our results indicate that the studied 2-methoxyphenylpiperazine derivatives
that possessed stronger α1A-adrenolytic properties (i.e., HBK-16, HBK-17, HBK-18,
and HBK-19) were the most active compounds in adrenaline-induced arrhythmia. Thus,
we suggest that the potent blockade of α1A-receptor subtype is essential to attenuate
adrenaline-induced arrhythmia.
Keywords: arrhythmia, antiarrhythmic agents, α1-adrenolytics, 2-methoxyphenylpiperazine, α1A-adrenoceptor
antagonist, α1B-adrenoceptor antagonist, α1D-adrenoceptor antagonist, hypotensive
INTRODUCTION
Arrhythmias are the most common causes of sudden cardiac
death (Deo and Albert, 2012). Despite numerous antiarrhythmic
drugs, pharmacotherapy is still ineffective in majority of patients.
Moreover, all antiarrhythmic agents acting via different ion
channels possess life-threatening proarrhythmic potential. Thus,
scientists are still looking for effective and safe compounds,
which will protect against arrhythmia and/or restore normal
heart rhythm.
Antiarrhytmic activity of pharmacological agents resulting
from their receptor-based mechanisms might be equally efficient
and much safer than that observed for classical antiarrhythmic
drugs. According to many studies, α1-adrenolytics may have
potential in the treatment of arrhythmias. Scientists agree that
the blockade of α1-, and particularly α1A-adrenoceptor may be
beneficial in restoring normal heart rhythm (reviewed in Hieble,
2000 and Shannon and Chaudhry, 2006). The α1-adrenoceptor
stimulation results in inositol trisphosphate (IP3) production,
and subsequent Ca2+ release from the sarcoplasmatic reticulum
(SR; Escobar et al., 2012). Although the regulation of Ca2+ level
in cardiomyocytes mainly depends on ryanodine receptors and
SR Ca2+ pump, the increased basal level of Ca2+ induced by
IP3 may also alter the electrical excitability of cardiomyocytes,
thus contributing to the development of arrhythmia e.g., atrial
(Zima and Blatter, 2004) or ventricular fibrillation (Proven et al.,
2006). Thereby, the blockade of α1-adrenoceptors may lead to
the stabilization of Ca2+ level producing antiarrhythmic effect in
arrhythmias induced by catecholamines e.g., catecholaminergic
polymorphic ventricular tachycardia. The above hypothesis was
supported by Suita et al. (2015), who demonstrated that prazosin
not only shortened norepinephrine-induced elongation of atrial
fibrillation in mice, but also attenuated norepinephrine-induced
SR Ca2+ leak and spontaneous SR Ca2+ release in cultured
atrium cardiomyocytes. This proves that α1-adrenoceptors may
have role in preventing cardiac arrhythmias. Numerous animal
studies confirmed this theory, showing antiarrhythmic properties
of α1-adrenolytics (Sapa et al., 2011; Kubacka et al., 2013a; Rapacz
et al., 2014, 2015b).
Since in our earlier experiments 2-methoxyphenylpiperazine
derivatives showed high affinity toward α1-adrenoceptors
(Pytka et al., 2015), in this study we aimed to determine
the role of α1-adrenoceptors subtypes (i.e., α1A, α1B) in
antiarrhythmic effect of six structurally similar derivatives of 2-
methoxyphenylpiperazine. We compared the activity of studied
compounds with carvedilol, which is β1- and α1-adrenoceptors
blocker with antioxidant properties.
MATERIALS AND METHODS
Animals
The experiments were carried out using male normotensive
Wistar rats [Krf: (WI) WU], weighing 200–250 g. Animals were
kept in plastic cages (three rats per cage) at constant room
temperature of 22 ± 2◦C, with 12:12 h light/dark cycle. Rats
had free access to food (standard pellet diet) and water. Each
experimental and control groups consisted of four to six animals.
The animals were killed by cervical dislocation immediately
after the experiment. All injections were given in a volume of 1
ml/kg. All experimental procedures were approved by the Local
Ethics Committee for Experiments onAnimals of the Jagiellonian
University in Krakow, Poland (approval numbers 110/2014 and
246/2015) and cared for in accordance with the Guide to the Care
and Use of Experimental Animals.
Drugs
Six studied compounds (Figure 1): 1-[(2,6-dimethylphenoxy)
ethoxyethyl]-4-(2-methoxyphenyl)piperazine hydrochloride
(HBK14), 1-[(2-chloro-6-methylphenoxy)ethoxyethyl]-4-(2-
methoxyphenyl)piperazine hydrochloride (HBK15), 1N-[3-
(2-chloro-5-methylphenoxy)propyl]-4N-(2-methoxyphenyl)
piperazine hydrochloride (HBK16), 1N-[3-(2,5-dimethylpheno
xy)propyl]-4N-(2-methoxyphenyl)piperazine hydrochloride
(HBK17), and 1N-[3-(2,4,6-trimethylphenoxy)propyl]-4N-(2-
methoxyphenyl)piperazine hydrochloride (HBK18), 1N-[3-(2,3,
5-trimethylphenoxy)propyl]-4N-(2-methoxyphenyl)piperazine
hydrochloride (HBK-19) were synthesized in the Department
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FIGURE 1 | The chemical structures of tested 2-methoxyphenylpiperazine derivatives. HBK-14, 1-[(2,6-dimethylphenoxy)ethoxyethyl]-4-(2-methoxyp
henyl)piperazine hydrochloride; HBK-15, 1-[(2-chloro-6-methylphenoxy)ethoxyethyl]-4-(2-methoxyphenyl)piperazine hydrochloride; HBK-16, 1N-[3-(2-chloro-5-meth
ylphenoxy)propyl]-4N-(2-methoxyphenyl)piperazine hydrochloride; HBK-17, 1N-[3-(2,5-dimethylphenoxy)propyl]-4N-(2-methoxyphenyl)piperazine hydrochloride;
HBK-18, 1N-[3-(2,4,6-trimethylphenoxy)propyl]-4N-(2-methoxyphenyl)piperazine hydrochloride; HBK-19, 1N-[3-(2,3,5-trimethylphenoxy)propyl]-4N-(2-methoxyphe
nyl)piperazine hydrochloride.
of Bioorganic Chemistry, Chair of Organic Chemistry, Faculty
of Pharmacy, Jagiellonian University (Waszkielewicz et al.,
2015). The investigated compounds were dissolved in saline
and administered intraperitoneally (i.p.) or intravenously (i.v.).
Thiopental (Rotexmedica, Germany) was dissolved in saline
and administered i.p. Chloroethylclonidine (Sigma, Germany),
noradrenaline (Sigma, Germany), johimbine (Tocris, United
Kingdom), propranolol (Fluka, USA), phentolamine (Sigma,
Germany) were dissolved in saline or dimethyl sulfoxide (DMSO,
Sigma, Germany) and used in radioligand or biofunctional
studies. Adrenaline (Polfa S.A., Warsaw), carvedilol (Sigma,
Germany), methoxamine (Sigma, China), calcium chloride
(Fluka, Germany), and barium chloride (Sigma, Germany) were
dissolved in saline and administered i.v. Heparin (Polfa S.A.,
Warsaw) was used as anticoagulant during experiments. The
control groups received 0.9% NaCl solution. Other chemicals
used were obtained from POCh (Polish Chemical Reagents,
Poland).
Radioligand Binding Assay
The α1- and β1-adrenoceptor radioligand binding assay was
performed on rat cerebral cortex. [3H]-prazosin (19.5 Ci/mmol,
α1-adrenoceptor) and [
3H]-CGP-12177 (48Ci/mmol, β1-
adrenergic receptor) were used. The brains were homogenized
in 20 volumes of an ice-cold 50mM Tris-HCl buffer (pH
7.6) and were centrifuged at 20,000 × g for 20 min (0−4◦C).
The cell pellet was resuspended in the Tris–HCl buffer and
centrifuged again. Radioligand binding assays were performed
in plates (MultiScreen/Millipore). The final incubation mixture
(final volume 300 µl) consisted of 240µl of the membrane
suspension, 30µl of [3H]-prazosin (0.2 nM), [3H]-CGP-
12177 (0.2 nM) solution and 30 µl of the buffer containing
seven to eight concentrations (10−11−10−4M) of the tested
compounds. In order to measure the unspecific binding,
10 µM phentolamine (for [3H]-prazosin) and 1 µM of
propranolol (for [3H]-CGP-12177) were applied. The incubation
was terminated by rapid filtration through glass fiber filters
(Whatman GF/C) using a vacuum manifold (Millipore).
The filters were then washed twice with the assay buffer and
placed in scintillation vials with a liquid scintillation cocktail.
Radioactivity was measured in a WALLAC 1409 DSA liquid
scintillation counter (Perkin Elmer, USA). All the assays were
made in duplicate and the inhibitory constants (Ki) were
estimated.
Influence on α1A-Adrenoceptors: Rat Tail
Artery
Rats were anesthetized with thiopental (75mg/kg i.p.) and the
middle part of the ventral caudal artery was removed, cleaned
of surrounded tissues and uncovered of endothelium by gentle
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rubbing in the Krebs-Henseleit solution. The isolated artery,
cut into ∼4 mm long rings, was then horizontally put up
between two stainless steel hooks (diameter 0.15 mm). One
hook was fastened to the bottom of the chamber and the other
to an isometric FDT10-A force displacement transducer (DMT
Model 750TOBS, Denmark), linked with Powerlab 4/26 analyzer
(ADInstruments), and processed by LabChart 7 software. The
isolated rings were incubated in the Krebs-Henseleit solution
(20ml) at the temperature 37◦C and pH 7.4 with constant
oxygenation (O2/CO2, 19:1). The initial optimal tissues tension
was set at 0.75 g. Chloroethylclonidine (3 µM) as the preferential
α1B-adrenoreceptor alkylating agent was used during incubation
and after 30min it was completely washed off. Through 100min
of equilibration tissues were stimulated with noradrenaline
(1 µM) four times with washing out until the contractile
response become constant. Two cumulative concentration-
response curves to noradrenaline, at an interval of 60min,
were established on each arterial ring both in the presence and
absence of antagonist. The incubation with antagonists went on
for 30min. The experiments were carried out in the constant
presence of yohimbine (0.1 µM) and propranolol (1µM) to
block α2- and β-adrenoceptors, respectively in order to minimize
the involvement of these adrenoceptors in the response to
noradrenaline.
Influence on α1B-Adrenoceptors: Mouse
Spleen
The influence on α1B-adrenoceptors was evaluated using the
isolated mouse spleen. The spleen was removed from male
mice right after killing the anesthetized animal by cervical
dislocation. The isolated tissue was incubated in 20ml cup filled
with the Krebs-Henseleit solution at the temperature 37◦C and
pH 7.4 with constant oxygenation (O2/CO2, 19:1). The initial
optimal tissues tension was set at 1.0 g. Through the 100min
of equilibration tissues were stimulated with noradrenaline
(0.1−10.0 µM) three times with washing out until the contractile
response become constant. Two cumulative concentration-
response curves to noradrenaline, at an interval of 60min, were
established on each tissue both in the presence and absence of
antagonist. The incubation with antagonists went on for 30min.
The experiments were carried out in the constant presence of
propranolol (1 µM) to block β-adrenoceptors, and minimize
the involvement of these adrenoceptors in the response to
noradrenaline.
Influence on α1D-Adrenoceptors: Rat Aorta
Finally, the influence on α1D-adrenoreceptors was investigated
using the isolated rat aorta. Rats anesthetized with thiopental
and killed by cervical dislocation had aorta removed, denuded
of endothelium and incubated in the Krebs-Henseleit solution
at the temperature 37◦C and pH 7.4 with constant oxygenation
(O2/CO2, 19:1). The aorta rings were maintained at optimal
tension of 2.0 g. During 3 h of equilibration tissues were
stimulated with noradrenaline three times (0.3 µM). Two
cumulative concentration-response curves to noradrenaline, at
an interval of 60min, were established on each tissue both
in the presence and absence of antagonist. The incubation
with antagonists went on for 30min. The experiments were
carried out in the constant presence of yohimbine (0.1 µM)
and propranolol (1 µM) to block α2- and β-adrenoceptors,
respectively.
Prophylactic Antiarrhythmic Activity in
Adrenaline-, Barium Chloride-, and
Calcium Chloride-Induced Arrhythmias
The procedures were performed according to the method
described by Szekeres and Papp (1975). The heart rate
disturbances were evoked by the intravenous administration
of adrenaline (20µg/kg), barium chloride (32 and 10mg/kg)
or calcium chloride (140 and 25mg/kg) solution into the
caudal vein in anesthetized rats (thiopental, 75mg/kg). The
studied compounds were administered i.p. 45min before the
injection of adrenaline, calcium chloride, or barium chloride. The
electrocardiogram (ECG) was recorded during the first 2min as
well as in the 5th, 10th, and 15thmin after the arrhythmogen
injection. The criterion of antiarrhythmic activity was the lack of
extrasystoles and inhibition of cardiac arrhythmia in comparison
with the control group in adrenaline-induced arrhythmia or the
progressive disappearance of the arrhythmia and reinstatement
of the sinus rhythm in barium chloride- and calcium chloride-
induced arrhythmias. The ED50 (a dose producing a 50%
inhibition of ventricular contractions) with 95% confidence
limits was determined by computer log-probit analysis according
to Litchfield andWilcoxon (1949) and Szekeres and Papp (1975).
The compounds were administered at the dose 10mg/kg. We
gradually decreased the dose by half until the disappearance of
antiarrhythmic activity.
Therapeutic Antiarrhythmic Activity in
Adrenaline-Induced Arrhythmia
The experiment was performed according to the method
described by Szekeres and Papp (1968). The arrhythmia
was evoked by the intravenous administration of adrenaline
(20µg/kg) into the caudal vein in anesthetized rats (thiopental,
75 mg/kg). The tested compounds were injected i.v. at the peak
of arrhythmia directly after adrenaline injection, at the ED84
(a dose producing a 84% inhibition of premature ventricular
contractions established in prophylactic adrenaline-induced
arrhythmia). The range of doses was 0.325−0.504mg/kg. The
ECG was recorded constantly for 5 min as well as in the 10th
and 15thmin of the experiment. The criterion of antiarrhythmic
activity was the reduction of premature ventricular contractions
in comparison with the control group (Sapa et al., 2011).
The Effect on Normal Electrocardiogram in
Rats
The experiment was carried out to exclude the influence of
tested compounds on normal ECG. The ECG was recorded
(ASPEL ASCARD B5 apparatus, standard lead II and paper
speed of 50mm/s) prior and also 5, 10, 15, 20, 30, 40, 50, and
60min after the i.p. administration of tested compounds. The
influence on QRS complex, PQ interval, heart rate (RR), and QTc
interval was determined. TheQTc was calculated according to the
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Bazzett’s formula: QTc = QT/√RR (De Clerck et al., 2002). The
compounds were administered at the ED84 (a dose producing a
84% inhibition of premature ventricular contractions established
in prophylactic adrenaline-induced arrhythmia).
Influence on Blood Pressure in
Normotensive Rats
Normotensive rats were anesthetized with thiopental (75mg/kg
ip). The right carotid artery was cannulated with a polyethylene
tube filled with heparin solution to allow pressure measurements,
using a Datamax apparatus (Columbus Instruments, USA;
Kubacka et al., 2013b). The tested compounds were administered
i.p. after 15min of stabilization period. The compounds were
administered at the dose 10mg/kg. We gradually decreased the
dose by half until the disappearance of antiarrhythmic activity.
Influence on Blood Vasopressor Response
in Rats
To verify if the hypotensive activity was a result of α-adrenolytic
properties, we studied the influence of tested compounds
on the pressor response to methoxamine (150µg/kg) The
experiment was carried out for all active compounds, which were
administered (i.v.) to the caudal vein at the lowest hypotensive
dose (Kubacka et al., 2013b). Pressor response to methoxamine
injected i.v. was measured before (control) and 5min after the
tested compounds.We administered the tested compounds at the
lowest possible doses, not to lose selectivity for α1-adrenoceptors.
Antioxidant Effect—Lipid Peroxidation in
Rat Brain Homogenate
This experiment was performed according to the method
described by Yue et al. (1992). The rat brain homogenate
containing 10mg tissue/ml was prepared in 0.9% saline. The rates
of membrane lipid peroxidation were measured by the formation
of thiobarbituric acid reactive substances (TBARS). Rat brain
homogenates (1ml) were incubated at 37◦C for 5min with 10
µl of a tested compound or vehicle. Lipid peroxidation was
initiated by the addition of 50 µl of 0.5mM FeCl2 and 50 µl of
2.0 mM ascorbic acid. After 30 min of incubation, the reaction
was stopped by adding 0.1ml of 0.2% butylated hydroxytoluene
(BHT). Thiobarbituric acid reagent was then added and the
mixture was heated for 15 min in a boiling water bath. Carvedilol
was used as reference compound. The compounds were tested at
a concentration of 10−3 M. The TBARsweremeasured at 532 nm.
Data Analysis
In radioligand binding studies, the obtained data were fitted
to a one-site curve-fitting equation with Prism 6.0 (GraphPad
Software), and inhibition constants (Ki) values were estimated
from the Cheng−Prusoff equation (Cheng and Prusoff, 1973):
Ki =
IC50
1+ LOKD
LO–labeled ligand concentration, KD–dissociation constant of
labeled ligand
In functional bioassays the concentration–response curves
were analyzed using GraphPad Prism 6.0 software (GraphPad
Software Inc., San Diego, CA, USA) as previously described
by Kubacka et al. (2013b). Data are means ± S.E.M. of
at least 4 separate experiments. To establish Hill slopes for
the agonist concentration–response curves and calculate EC50
values, curves were fitted to all the data by non-linear regression.
The EC50 value in the presence and absence of antagonists
was used to ascertain the concentration ratio (CR). Schild
analysis was performed. If the slope was not significantly
different from unity, the relative antagonistic potencies (pA2:
−log of the concentration of an antagonist that doubles the
concentration of the agonist needed to elicit the original
submaximal response obtained in the absence of antagonist)
were determined by plotting the log (CR-1) against the −log of
antagonist concentration (Arunlakshana and Schild, 1959).
In case of in vivo experiments the results are presented as
the means ± S.E.M. Statistically significant differences between
groups were calculated using one-way analysis of variance
(ANOVA) with repeated measurements followed by Dunnett’s
or Bonferroni’s test post-hoc or Student’s t-test. The criterion for
significance was set at p< 0.05.
Antioxidant activity was expressed as the percentage
reduction of the sample absorbance during the reaction at
wavelength 532 nm.
The log-probit method described by Litchfield and Wilcoxon
(1949) was used to determine median effective doses (ED50—
doses producing 50% inhibition of premature ventricular
contractions) and doses producing 84% of the maximal effect
(ED84) for compounds in arrhythmia models.
RESULTS
Affinity for Adrenoceptors
All studied compounds possessed high affinity for α1-
adrenoceptors but none of them bound to β1-adrenoceptors
(Table 1).
Functional Affinity for α1A-, α1B-, and
α1D-adrenoceptors
The tested compounds antagonized noradrenaline evoked
contraction in isolated rat aorta and tail artery, as well
as mouse spleen, and concentration-dependently, shifted the
noradrenaline response to the right, without affecting the
maximum response. The obtained pA2 values with Schild
slopes not significantly different from unity indicated a
competitive antagonism at α1A-, α1B-, and α1D-adrenoceptors
(Tables 2A,B).
HBK-14, HBK-15, HBK-16, HBK-17, and HBK-18 showed
stronger antagonistic properties at α1D- than α1A- or α1B-
adrenoceptors. HBK-19 antagonized α1A-adrenoceptors stronger
than two other subtypes. All compounds antagonized α1A-
adrenoceptors stronger than α1B-subtype. Among the studied
compounds the strongest antagonist of α1A-adrenoceptor was
HBK-19, α1B-adrenoceptor—HBK-18, and α1D-adrenoceptor—
HBK-16.
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The Effect on Normal Electrocardiogram in
Rats
Table 3 shows the influence of tested compounds on normal ECG
in rats.
HBK-14 and HBK-15 administered at the dose 6.154 and
20.218mg/kg, respectively did not influence the ECG parameters
throughout the experiment. HBK-16 at the dose 0.363mg/kg
did not influence PQ interval, QRS complex or QTc interval
but it significantly reduced heart rate by 11−13%, since the
40thmin of the observation. Similarly, HBK-17 at the dose
0.504mg/kg significantly decreased heart rate by 9−12%, 20min
after administration, without affecting PQ interval, QRS complex
or QTc interval. HBK-18 at the dose 0.325mg/kg significantly
TABLE 1 | The affinity of tested compounds for α1- and β1-adrenoceptors.
Compound Adrenergic receptors Ki (nM)
α1 β1
HBK-14 22.8a n.aa
HBK-15 13.1a n.aa
HBK-16 5.0 n.a.
HBK-17 12.9 n.a.
HBK-18 5.2 n.a.
HBK-19 22.7 n.a.
Phentolamine 18.3 −
Propranolol − 7.1
Carvedilol 2.2b 0.8b
Inhibition constants (Ki ) were calculated according to the equation of Cheng and Prusoff
(1973). The compounds were tested in three separate experiments in duplicates. n.a.,
compound did not bind to the receptor at the concentration 10−5 M.
aPytka et al. (2015).
bPönicke et al. (2002).
reduced the heart rate by 13−23%, since the 15thmin of the
observation and did not affect PQ interval, QRS complex or
QTc interval. HBK-19 at the dose 0.444mg/kg between the 15th
and 30thmin after administration reduced heart rate by 21−22%
without the influence on PQ interval, QRS complex, or QTc
interval.
Prophylactic Antiarrhythmic Activity in
Adrenaline-, Barium Chloride-, and
Calcium Chloride-Induced Arrhythmias
In anesthetized rats i.v. injection of adrenaline (20µg/kg) caused
atrioventricular disturbances, ventricular and supraventricular
extrasystoles in 100% of the animals, which led to the death
of ∼70% of the animals. The studied compounds administered
45 min (i.p.) prior to adrenaline, decreased the number of
extrasystoles and mortality (Figures 2, 3, Table 4). Table 5 shows
the ED50 values (doses producing 50% inhibition of premature
ventricular contractions).
The injection (i.v.) of barium chloride (32mg/kg) caused rapid
ventricular extrasystoles in all animals (100%), which led to the
death within 3−5min. Lower dose of barium chloride (10mg/kg)
caused ventricular extrasystoles in around 60% of rats and did not
lead to the death of animals. We did not observe a reproducible
negative effect on heart rhythm when barium chloride was
used at the dose 10mg/kg. None of the tested compounds
administered (i.p.) 45min before barium chloride were active
in barium chloride-induced model of arrhythmia (data not
shown).
In anesthetized rats injection (i.v.) of calcium chloride
(140mg/kg) caused rapid ventricular fibrillation in all animals
(100%), which led to death within 3−5min. The intravenous
administration of calcium chloride (25mg/kg) caused ventricular
fibrillation in all animals, but did not lead to the death of rats.
TABLE 2A | The functional affinities of tested and reference compounds for α1-adrenergic receptor subtypes.
Compound Isolated tissues, α1-adrenoceptor subtypes, pA2 ± S.E.M. (slope ± S.E.M.)
Rat tail artery Mouse spleen Rat aorta
α1A α1B α1D
HBK-14 7.99 ± 0.09 (0.97 ± 0.15) 7.70 ± 0.08 (1.03 ± 0.03) 8.86 ± 0.06 (1.09 ± 0.10)
HBK-15 7.71 ± 0.07 (1.01 ± 0.18) 7.67 ± 0.09 (0.96 ± 0.01) 8.90 ± 0.09 (1.09 ± 0.09)
HBK-16 8.75 ± 0.03 (1.06 ± 0.08) 8.21 ± 0.07 (1.03 ± 0.12) 9.14 ± 0.03 (1.11 ± 0.12)
HBK-17 8.15 ± 0.08 (0.91 ± 0.05) 7.94 ± 0.06 (0.91 ± 0.03) 8.83 ± 0.09 (1.01 ± 0.07)
HBK-18 8.49 ± 0.09 (1.10 ± 0.06) 8.35 ± 0.05 (1.03 ± 0.18) 8.92 ± 0.08 (1.01 ± 0.05)
HBK-19 8.91 ± 0.09 (0.96 ± 0.05) 8.07 ± 0.07 (1.06 ± 0.05) 8.31 ± 0.08 (1.03 ± 0.09)
Prazosin 8.93 ± 0.03a 9.07 ± 0.09b 8.85 ± 0.09b
Tamsulosin 10.32 ± 0.05c 8.33 ± 0.08d 9.56 ± 0.07d
The functional affinities were determined in the rat tail artery (α1A-adrenoceptor subtype), mouse spleen (α1B-adrenoceptor subtype), rat aorta (α1D-adrenoceptor subtype). Noradrenaline
was used as α1-adrenergic receptor agonist. The highest pA2 values for each receptor subtype are in bold font. Antagonist potency of the tested compounds was expressed as pA2 ±
S.E.M. pA2 was defined as −log of the concentration of an antagonist that doubles the concentration of the agonist necessary to elicit the original submaximal response in the absence
of antagonist. pA2 values were obtained from the linear regression of Schild plot (Arunlakshana and Schild, 1959). Each value was the mean ± S.E.M. of 4–8 experimental results.
aParés-Hipólito et al. (2006).
bEltze (1996).
cJähnichen et al. (2004).
dEltze et al. (1999).
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None of the tested compounds administered (i.p.) 45min prior
to calcium chloride were active in the above model of arrhythmia
(data not shown).
Therapeutic Antiarrhythmic Activity in
Adrenaline-Induced Arrhythmia
All tested compounds administered i.v. at the peak of
adrenaline-induced arrhythmia (20µg/kg) reduced the number
of premature ventricular contractions (Figure 4).
Influence on Blood Pressure in
Normotensive Rats
Table 6 presents the lowest dose of each tested compound,
which significantly lowered systolic and diastolic blood pressure
in rats.
HBK-14 at the dose 0.625mg/kg, 10min after injection,
significantly reduced systolic blood pressure by 5−10%, and
diastolic blood pressure by 9−14% since the 20thmin of
the observation. HBK-15 at the dose 5.0mg/kg significantly
reduced systolic blood pressure by 13−19%, and diastolic blood
pressure by 13−20%, 5 min after administration. HBK-16 at
the dose 0.1mg/kg, 20min after administration, significantly
reduced systolic blood pressure by 8−11% and diastolic
blood pressure by 6−10%. HBK-17 at the dose 0.1mg/kg
significantly reduced systolic blood pressure by 8−11% and
diastolic blood pressure by 10−16%, 20 min after administration.
HBK-18 at the dose 0.01mg/kg, from the 20thmin of the
observation, significantly reduced systolic and diastolic blood
pressure by 23−28 and 16−18%, respectively. HBK-19 at the
dose 0.625mg/kg since the 5th min after i.p. administration,
significantly reduced systolic blood pressure by 5−17%, whereas
diastolic blood pressure by 9−15% since the 10th min of the
observation.
Influence on Blood Vasopressor Response
in Rats
In the control group the increase of blood pressure after
methoxamine (150µg/kg) was ranging from 62.7 ± 10.4 to 94.2
± 2.7mmHg. Figure 5 shows that all tested compounds at the
lowest hypotensive doses, significantly antagonized the pressor
response to methoxamine.
Influence on Lipid Peroxidation in Rat
Brain Homogenate
Carvedilol, HBK-16, HBK-17, HBK-18, and HBK-19 inhibited
lipid peroxidation (Table 7). HBK-14 and HBK-15 were inactive
in this test.
DISCUSSION
We found that the studied 2-methoxyphenylpiperazine
derivatives that possessed stronger α1A-adrenolytic properties
(i.e., HBK-16, HBK-17, HBK-18, and HBK-19) were the most
active compounds in adrenaline-induced arrhythmia. Their
antiarrhythmic (but not antioxidant) activity was comparable to
that of carvedilol. The tested compounds showed hypotensive
TABLE 2B | The affinity of tested compounds for α1-adrenergic receptor
subtypes.
Compound The affinity for α1-adrenergic receptor subtypes
HBK-14 α1D > α1A > α1B
HBK-15 α1D > α1A > α1B
HBK-16 α1D > α1A > α1B
HBK-17 α1D > α1A > α1B
HBK-18 α1D > α1A > α1B
HBK-19 α1A > α1D > α1B
The functional affinities were determined in the rat tail artery (α1A-adrenoceptor subtype),
mouse spleen (α1B-adrenoceptor subtype), rat aorta (α1D-adrenoceptor subtype).
effect resulting from their α1-adrenolytic properties. HBK-19
was the only compound in the group that did not lower blood
pressure at antiarrhythmic doses.
Scientists reported that 2-methoxyphenylpiperazine
derivatives often interact with adrenergic receptors (Handzlik
et al., 2008; Kubacka et al., 2013a; Rapacz et al., 2014, 2015a,b).
Thus, we evaluated the affinity of the studied compounds for
α1-and β1-adrenoceptors. The radioligand studies revealed that
HBK-16, HBK-17, HBK-18, and HBK-19 possessed high affinity
for α1-, but not β1-adrenoceptors. This is in agreement with our
previous experiments on 2-methoxyphenylpiperazine derivatives
i.e., HBK-14 and HBK-15, which showed no affinity for β1- and
high affinity for α1-adrenoreceptors (Pytka et al., 2015).
Studies proved that cardiac myocytes functionally
express α1A- and α1B-adrenoceptors. O’Connell et al. (2003)
demonstrated that despite the presence of α1D-adrenoceptors
mRNA, rodent cardiac myocytes did not express α1D-subtype
protein by binding. However, Chalothorn et al. (2003) showed
that α1D-adrenoceptors might be expressed in the coronary
vasculature. Thus, α1A- and α1B-adrenoceptors may play
important role in the development of arrhythmias induced
by catecholamines, while α1D-subtype in ischemia-induced
arrhythmias.
Scientists indicated that agents which block
α1A-adrenoceptors may have antiarrhythmic potential (Hieble,
2000). Harrison et al. (1998) showed that hearts from transgenic
rats expressing constitutively active α1B-adrenoceptors, and
having 50% reduced α1A-mRNA levels, were less sensitive to
ischemia-induced ventricular tachycardia than normal rats. Lee
and Rosen (1993) proved that the blockade of α1B receptors
by chlorethylclonidine increased the amplitude of delayed
afterdepolarizations induced by calcium and phenylephrine.
Altogether, these findings suggest that agents, which block
α1A-adrenoceptors stronger than α1B subtype, may have
antiarrhythmic potential.
Therefore, we determined the selectivity of studied
compounds at α1-adrenoceptor subtypes. Biofunctional
assays revealed that all compounds competitively blocked
α1A, α1B, and α1D subtypes. HBK-19 and HBK-16 were the
strongest α1A-adrenoceptor antagonists, while HBK-14 and
HBK-15 were the weakest. Although we did not find highly
selective compounds, all 2-methoxyphenylpiperazine derivatives
antagonized α1A-adrenoceptors stronger than α1B subtype.
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TABLE 3 | The influence of the tested compounds on ECG.
Compound Parameters Time of observation (min)
0 5 10 15 20 30 40 50 60
HBK-14 Beats/min 366.0±10.8 369.8±10.0 367.0± 9.9 359.8± 9.5 358.4± 11.4 359.8± 9.6 362.6± 11.9 361.6± 12.6 364.6±11.2
PQ (ms) 47.1±1.1 46.0±1.0 46.3± 0.9 47.5± 1.3 46.3± 1.0 48.8± 1.9 48.2± 2.1 47.3± 1.6 48.4±0.9
QRS (ms) 26.1±0.7 25.8±0.5 27.6± 1.0 27.0± 0.6 26.3± 0.4 26.7± 0.9 26.1± 0.4 26.7± 1.0 27.5±0.7
QT (ms) 85.8±1.3 85.0±4.1 88.7± 1.9 89.0± 2.4 88.2± 2.9 89.6± 1.7 89.0± 2.1 87.9± 1.2 89.5±2.4
QTc (ms) 211.7±3.2 209.2±8.3 214.8± 5.0 212.9± 5.7 212.5± 4.6 214.1± 5.0 214.1± 5.2 210.9± 5.1 214.1±4.2
HBK-15 Beats/min 353.8±10.2 365.4±15.3 350.8± 10.5 333.9± 12.4 327.6± 20.3 340.1± 17.7 339.5± 20.4 350.1± 17.9 351.8±15.0
PQ (ms) 48.7±1.0 48.4±0.5 48.2± 1.0 46.6± 0.9 47.6± 0.5 46.1± 0.3 46.1± 0.7 47.5± 0.7 48.0±1.1
QRS (ms) 25.7±0.7 26.3±0.9 26.1± 1.1 25.6± 1.2 26.3± 0.5 26.4± 0.9 28.0± 0.9 26.1± 1.2 26.3±0.5
QT (ms) 87.3±1.4 86.5±1.3 87.2± 2.0 87.5± 2.0 87.2± 0.6 86.7± 1.1 87.0± 1.5 88.2± 0.8 88.5±2.2
QTc (ms) 212.0±5.0 213.6±7.0 211.3± 6.2 207.1± 6.8 203.7± 7.2 206.4± 7.9 206.5± 6.6 212.7± 6.9 213.9±7.2
HBK-16 Beats/min 329.6±9.8 331.4±12.5 330.1± 12.4 319.4± 10.3 310.6± 9.8 302.8± 11.0 294.1± 12.2a 291.4± 13.0b 288.0±13.8b
PQ (ms) 64.4±1.1 63.7±1.1 63.6± 0.9 63.9± 1.1 65.1± 1.2 64.4± 1.1 65.9± 0.8 67.3± 1.6 68.2±0.9
QRS (ms) 21.7±2.2 21.7±2.2 21.7± 2.2 21.7± 2.2 21.7± 2.2 21.7± 2.2 21.7± 2.2 22.0± 2.1 22.3±2.0
QT (ms) 51.4±3.5 51.2±3.5 51.2± 3.3 50.1± 3.6 51.4± 3.1 52.7± 3.7 53.5± 2.8 54.7± 2.8 55.5±2.4
QTc (ms) 120.5±8.7 120.7±9.7 120.2± 8.8 115.8± 9.6 117.3± 8.7 119.0± 10.3 118.9± 8.4 121.1± 8.7 122.0±7.7
HBK-17 Beats/min 365.2±15.0 359.4±16.6 348.7± 15.0 341.1± 13.4 333.5± 13.3b 327.4± 11.8c 333.0± 10.6b 323.8± 14.1c 320.9±13.4c
PQ (ms) 66.5±3.7 65.0±3.3 64.3± 3.4 65.6± 3.7 65.9± 3.4 67.7± 4.0 67.0± 3.2 67.4± 3.5 67.6±3.3
QRS (ms) 23.3±1.8 23.3±1.4 23.0± 1.7 23.3± 2.0 22.7± 1.8 22.7± 2.0 23.0± 1.7 23.3± 1.4 23.0±1.7
QT (ms) 55.2±2.3 55.3±0.9 55.7± 1.1 57.4± 0.8 57.7± 1.8 60.3± 1.1 61.3± 1.6 60.4± 2.0 61.5±2.3
QTc (ms) 135.8±5.3 135.2±3.3 134.1± 3.1 136.5± 2.3 135.6± 3.5 140.7± 3.7 144.3± 5.0 140.2± 5.4 142.0±5.0
HBK-18 Beats/min 328.0±7.4 306.9±9.0 298.7± 8.9 284.7± 7.6a 273.9± 8.0b 267.4± 17.5c 260.3± 22.8c 258.9± 25.4c 252.3±25.1c
PQ (ms) 61.3±4.6 61.5±6.3 57.4± 4.2 55.8± 1.6 51.9± 3.8 56.9± 3.5 57.4± 3.1 59.0± 3.8 59.6±4.7
QRS (ms) 28.1±3.1 30.4±3.2 30.8± 3.6 27.0± 2.9 29.1± 2.7 28.5± 2.8 28.6± 2.8 27.6± 3.0 30.9±3.8
QT (ms) 73.9±6.2 77.0±7.0 77.7± 4.9 76.1± 5.8 77.9± 4.2 75.3± 3.2 76.9± 4.9 76.0± 2.9 76.7±3.5
QTc (ms) 172.4±13.5 174.2±16.3 173.4± 11.7 166.4± 14.5 166.9± 11.1 159.0± 9.7 160.4± 14.4 157.2± 9.9 157.1±12.0
HBK-19 Beats/min 355.3±19.7 349.7±25.3 339.1± 21.0 280.1± 1.1c 277.2± 5.0c 278.2± 6.7c 332.8± 18.9 396.8± 31.8 398.0±32.4
PQ (ms) 56.7±0.7 56.6±0.0 56.0± 0.0 58.2± 1.8 60.1± 1.3 60.1± 1.7 59.3± 0.7 55.1± 0.3 56.3±1.1
QRS (ms) 35.7±1.0 34.7±1.6 34.0± 0.3 32.0± 1.2 32.7± 0.4 34.3± 0.2 32.0± 3.1 36.0± 1.5 30.3±1.1
QT (ms) 76.4±8.2 76.9±1.1 77.5± 0.5 82.2± 2.2 84.3± 1.1 82.2± 0.4 81.5± 2.5 76.5± 0.5 80.2±0.4
QTc (ms) 186.9±24.6 185.5±9.5 184.2± 6.9 177.6± 4.4 181.1± 4.1 177.0± 3.0 192.2± 11.2 196.2± 6.9 206.3±9.6
Rats were anesthetized intraperitoneally (i.p.) with thiopental (75 mg/kg). The compounds were administered (i.p.) at the ED84 obtained in prophylactic adrenaline-induced arrhythmia
i.e., 6.154 mg/kg (HBK-14), 20.218 mg/kg (HBK-15), 0.363mg/kg (HBK-16), 0.504 mg/kg (HBK-17), 0.325 mg/kg (HBK-18), 0.444 mg/kg (HBK-19). The data are expressed as mean
± S.E.M. Statistical analysis: one-way ANOVA with repeated measurements, Dunnet post-hoc test,
ap < 0.05,
bp < 0.01,
cp < 0.001 vs. initial values. n = 4–6 rats per group.
HBK-19 showed the greatest difference in pA2 values—it
blocked α1A-adrenoceptors around seven-fold stronger than α1B
subtype.
Since all studied compounds blocked α1A- and α1B-
adrenoceptors, we decided to examine their antiarrhythmic
activity. We also investigated whether antiarrhythmic activity
depended on the strength of α1A-adrenoceptor blockade or the
differences between pA2 values for α1A- and α1B-adrenoceptors.
To determine antiarrhythmic effect, we used three models of
arrhythmia i.e., adrenaline-, barium chloride-, and calcium
chloride-induced.
All compounds showed antiarrhythmic activity in adrenaline-
induced model of arrhythmia, and reduced mortality of rats.
HBK-18 possessed the strongest prophylactic antiarrhythmic
properties, but ED50 values for HBK-16, HBK-17, and HBK-19
were also very low. Except for HBK-14 andHBK-15, prophylactic
antiarrhythmic activities of compounds in adrenaline-induced
arrhythmia were comparable to that of carvedilol (reference
drug). We think that the weak antiarrhythmic activity of HBK 14
andHBK 15may be due to their weaker α1-adrenolytic properties
(see Table 2), which are crucial for antiarrhythmic effect in the
applied model of arrhythmia. Since the compounds used in the
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FIGURE 2 | Representative ECGs after treatment with adrenaline and/or HBK-16, HBK-17, HBK-18, and HBK-19 in rats. (A) Normal reading (Control). (B)
Arrhythmia control—adrenaline (20 µg/kg, i.v.). (C) Adrenaline-induced arrhythmia (20µg/kg, i.v.)+HBK-16 (0.3mg/kg, i.v. injection 45min prior to adrenaline). (D)
Adrenaline-induced arrhythmia (20µg/kg, i.v.)+HBK-17 (0.3mg/kg, i.v. injection 45min prior to adrenaline). (E) Adrenaline-induced arrhythmia (20µg/kg, i.v.)+HBK-18
(0.3mg/kg, i.v. injection 45min prior to adrenaline). (F) Adrenaline-induced arrhythmia (20µg/kg, i.v.)+HBK-19 (0.3mg/kg, i.v. injection 45min prior to adrenaline).
FIGURE 3 | The effect of adrenaline and studied compounds on mortality of rats in prophylactic adrenaline-induced arrhythmia. Rats were anesthetized
with intraperitoneal (i.p.) injection of thiopental (75mg/kg). The tested compounds were administered (i.p.) 45min before the experiment. The observation was carried
out for 15 min after the intravenous injection of adrenaline (20µg/kg). n = 5−6 animals per group.
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TABLE 4 | The antiarrhythmic activity of 2-methoxy phenylpiperazine
derivatives in prophylactic model of adrenaline induced arrhythmia.
Compound Dose Extrasystoles Bigeminy Bradycardia Blocks
(mg/kg) (%) (%) (%) (%)
Adrenaline – 66.7 33.3 66.7 50.0
HBK-14 2.5 100.0 50.0 83.3 83.3
5 50.0 33.3 50.0 33.3
10 16.7 16.7 50.0 33.3
HBK-15 2.5 66.7 33.3 66.7 66.7
5 50.0 16.7 66.7 50.0
10 33.3 16.7 50.0 33.3
HBK-16 0.1 83.3 33.3 66.7 50.0
0.2 33.3 16.7 50.0 33.3
0.3 16.7 – 33.3 16.7
HBK-17 0.1 66.7 50.0 67.7 67.7
0.2 50.0 33.3 50.0 33.3
0.3 16.7 16.7 33.3 16.7
HBK-18 0.1 83.3 50.0 66.7 66.7
0.2 50.0 16.7 50.0 33.0
0.3 16.7 12.0 16.3 16.3
HBK-19 0.1 66.7 33.3 66.7 50.0
0.2 50.0 16.7 33.3 33.3
0.3 16.7 – 16.7 16.7
Rats were anesthetized with intraperitoneal (i.p.) injection of thiopental (75mg/kg). The
tested compounds were administered (i.p.) 45min before the experiment. The observation
was carried out for 15min after the intravenous injection of adrenaline (20µg/kg) i.e.,
during the first 2min, in the 5, 10, and 15thmin. n = 5−6 animals per group.
TABLE 5 | Prophylactic antiarrhythmic activities of tested compounds and
carvedilol in adrenaline-induced arrhythmia.
Compound ED50(mg/kg)
HBK-14 3.88 (2.68−5.61)
HBK-15 4.80 (2.32−9.93)
HBK-16 0.20 (0.10−0.39)
HBK-17 0.20 (0.12−0.35)
HBK-18 0.18 (0.11−0.29)
HBK-19 0.21 (0.13−0.34)
Carvedilol 0.36 (0.16−0.80)
Rats were anesthetized with intraperitoneal (i.p.) injection of thiopental (75mg/kg). The
tested compounds were administered (i.p.) 45min before the experiment. The observation
was carried out for 15min after the intravenous injection of adrenaline (20µg/kg) i.e.,
during the first 2min, in the 5, 10, and 15thmin. The ED50 values with confidence limits
were calculated according to the methods described by Litchfield and Wilcoxon (1949).
Each value was obtained from three experimental groups. n = 5−6 animals per group.
experiments did not present potent selectivity toward different
subtypes of α1−adrenoceptors, we cannot definitely conclude
which receptor subtype should be primarily blocked to achieve
antiarrhythmic effect. Although, HBK-19 showed the greatest
FIGURE 4 | Therapeutic antiarrhythmic activities of tested compounds
in adrenaline-induced arrhythmia. Rats were anesthetized with
intraperitoneal injection of thiopental (75mg/kg). The tested compounds were
administered intravenously (i.v.) at the ED84 obtained in prophylactic
adrenaline-induced arrhythmia i.e., 0.363mg/kg (HBK-16), 0.504mg/kg
(HBK-17), 0.325mg/kg (HBK-18), 0.444mg/kg (HBK-19), 0.979mg/kg
(carvedilol). Data are reported as means ± S.E.M. Statistical analysis:
Student’s t-test; **p < 0.01, ***p < 0.001. n = 5−6 animals per group.
difference in pA2 values for the α1A- and α1B receptor subtypes,
it did not possess the strongest antiarrhythmic properties.
Similarly, according to the studies performed by Koshimizu
et al. (2004), the pA2 value for α1A−adrenoceptor subtype for
carvedilol was 9.0, whereas for α1B−adrenoceptor was 10.0.
Carvedilol showed comparable properties in adrenaline-induced
arrhythmia model. Thus, we claim that the potent blockade of
α1A-receptor subtype is essential to attenuate adrenaline-induced
arrhythmia, but the role of α1B-adrenoceptor blockade needs
further studies. Carvedilol is a potent β1- and α1-adrenoceptors
blocker with antioxidant activity. Surprisingly, despite the
fact that carvedilol blocked both β1- and α1-adrenoceptors,
and the studied compounds only α1-adrenoceptors, their
antiarrhythmic effect was comparable. Therefore, we suggest
that this may indicate more important role of α1- than
β1-adrenoceptors blockade in adrenaline-induced arrhythmia
model.
Arrhythmia models induced by calcium or sodium chloride
are associated with the changes in intracellular ion concentration.
These changes are ion channel dependent, and their dynamics
and amplitude are high. In arrhythmias induced by adrenaline,
the stimulation of adrenergic receptors also leads to ion level
changes (primarily Ca2+), but these changes are not as rapid.
Their amplitude and dynamics are much lower than the above.
None of the compounds showed activity in barium chloride- or
calcium chloride-induced arrhythmias. Therefore, we can assume
that the blockade of sodium or calcium channels was not the
predominant mechanism of antiarrhythmic effect of the studied
compounds.
We decided to test therapeutic antiarrhythmic potential of
the most active compounds (i.e., HBK-16, HBK-17, HBK-18,
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TABLE 6 | The hypotensive activity of 2-methoxyphenylpiperazine derivatives in normotensive rats.
Compound Dose (mg/kg) Pressure Time of observation (min)
Control 5 10 20 30 40 50 60
HBK-14 0.625 Systolic 138.3± 6.8 135.2± 7.3 131.2±6.8c 127.3± 6.6c 125.3± 7.0c 124.2±7.0c 127.3± 6.3c 128.2±5.4c
Diastolic 106.7± 4.3 105.2± 6.1 103.0±5.8 97.3± 6.0c 95.2± 6.1c 92.3±6.2c 94.0± 5.8c 98.0±5.1c
HBK-15 5.0 Systolic 139.0± 2.7 121.2± 4.8c 116.3±6.0c 112.0± 5.5c 112.2± 4.2c 112.5±4.4c 113.2± 3.7c 117.3±3.0c
Diastolic 110.3± 2.2 96.3± 3.7c 92.0±4.3c 88.5± 3.5c 88.3± 2.9c 91.0±3.2c 90.2± 2.7c 93.0±1.2c
HBK-16 0.1 Systolic 124.7± 3.1 123.2± 3.3 121.2±3.2 114.8± 2.0b 113.0± 2.4c 110.3±2.1c 110.8± 2.0b 110.7±1.9c
Diastolic 97.0± 4.3 95.0± 5.1 93.7±5.1 91.3± 5.0b 89.8± 5.2a 87.7±4.7b 88.0± 4.3c 87.7±4.6b
HBK-17 0.1 Systolic 136.8± 3.7 132.7± 4.8 130.5±4.7 125.5± 4.9b 124.2± 4.4b 121.7±3.9b 121.5± 3.4a 121.2±3.9b
Diastolic 110.7± 4.6 108.2± 5.2 105.8±4.3 99.3± 4.7a 96.8± 4.0b 94.0±3.7b 93.3± 4.0b 94.5±4.3b
HBK-18 0.01 Systolic 125.7± 8.2 117.7± 9.1 112.7±7.7 96.5± 8.9b 93.8± 8.7c 91.8±10.0b 90.7± 8.6b 90.2±9.2a
Diastolic 94.3± 6.4 90.7± 7.1 85.5±7.5 79.5± 7.8a 78.3± 7.2a 78.8±7.0b 78.7± 5.6c 77.5±6.0b
HBK-19 0.625 Systolic 127.0± 4.0 121.0± 4.0b 116.0±3.5c 111.5± 3.2c 110.0± 2.3c 107.5±3.2c 106.0± 3.5c 106.0±4.0c
Diastolic 98.0± 4.6 94.5± 2.6 87.5±0.4c 89.0± 2.3b 87.0± 2.9c 84.5±1.4c 83.5± 1.4c 84.0±0.6c
Rats were anesthetized intraperitoneally (i.p.) with thiopental (75mg/kg). The compounds were administered (i.p.). The results present the lowest hypotensive dose. The data are the
means of six experiments ± S.E.M. Statistical analysis: one-way ANOVA test with repeated measurements, Dunnet post-hoc test.
ap < 0.05,
bp < 0.01,
cp < 0.001 vs. control values. n = 6 rats per group.
and HBK-19) in adrenaline-induced model of arrhythmia. The
studied compounds restored normal heart rhythm administered
at the peak of arrhythmia, but the strongest therapeutic
antiarrhythmic activity showed HBK-18. The results of this
experiments correlate with the results obtained in prophylactic
adrenaline-induced arrhythmia model.
Antiarrhythmic agents have proarrhythmic potential, thus we
evaluated the influence of studied compounds on normal ECG
in rats. Only HBK-14 and HBK-15 did not influence ECG at
ED84 obtained in prophylactic adrenaline-induced arrhythmia
model. The rest of compounds significantly decreased heart
rate. Williamson et al. (1994) proved that stimulation of α1A-
adrenoceptors resulted in positive chronotropic effect. This
suggests that the decrease in heart rate observed after treatment
with HBK-16, HBK-17, HBK-18, and HBK-19 was a result of α1A
receptor blockade.
The QT interval represents electrical depolarization
and repolarization of ventricles. The prolongation of QT
interval indicates the potential of a drug to cause ventricular
tachyarrhythmias like torsades de pointes. The QTc adjusts
the QT interval for heart rate extremes. In this study we used
Bazett’s equation to calculate QTc. Nevertheless, we need to
point out that even though Bazett’s formula is very often used
for QT correction, it has many limitations (e.g., over- and
under-correction of high or low heart rhythms). Rodents’ heart
rate values can be several times higher than those observed
in humans (Kmecova and Klimas, 2010). Since heart rhythm
significantly influences QTc, this might be the reason for the
observed differences in baseline QTc in our experiments. We
showed that none of the compounds affected QTc at ED84,
therefore we can assume that they did not have proarrhythmic
potential at antiarrhythmic doses.
Our findings are in agreement with the results obtained
by other researchers, showing that phenylpiperazine derivatives
possessed α1-adrenolytic properties, as well as prophylactic
and/or therapeutic activity in adrenaline-induced arrhythmia
(Dylag et al., 2004; Handzlik et al., 2012; Kubacka et al., 2013a,b).
When discussing adrenaline-induced arrhythmias we could
neglect the role of α1D-adrenoceptors, since their blockade
should not have a direct influence on cardiac myocytes.
Nevertheless, in animal studies on drug candidates, we cannot
entirely ignore the role of α1D-subtype. α1D-Adrenoceptors
blockade in blood vessels might significantly lower blood
pressure, which due to the baroreflex might increase heart rate,
and contribute to arrhythmia.
Since all studied compounds blocked α1D-adrenoceptor, and
these receptors among others regulate blood pressure, we
evaluated their influence on blood pressure in rats. All tested
compounds showed hypotensive properties. HBK-18 showed
the strongest hypotensive activity, while HBK-15 the weakest.
Interestingly, the results of this experiment did not correlate with
the functional bioassays, where the strongest α1D-adrenoceptor
blocking properties showed HBK-16. We suspect that this may
be due to the differences in receptor binding dynamics, but this
issue would require further experiments. Regarding the case of
HBK-19, the lowest dose that reduced blood pressure was around
three-fold higher than ED50 value in prophylactic adrenaline-
induced arrhythmia. For antiarrhythmic drugs, hypotensive
activity is not desirable, since α1-adrenoceptor blockers acting
in the periphery, may induce reflex tachycardia, and contribute
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FIGURE 5 | The effect of tested compounds on the blood pressure
response to methoxamine. Rats were anesthetized with intraperitoneal
injection of thiopental (75mg/kg). The studied compounds were administered
intravenously (i.v.), at the lowest hypotensive doses i.e., 0.625mg/kg
(HBK-14), 5.0mg/kg (HBK-15), 0.1mg/kg (HBK-16), 0.1mg/kg (HBK-17),
0.01mg/kg (HBK-18), 0.625mg/kg (HBK-19). Methoxamine (MET) was
administered at the dose 150µg/kg (i.v.). All values represent means ± S.E.M.
Statistical analysis: Student’s t-test; *p < 0.05, **p < 0.01, compared to the
initial maximal response (obtained before the administration of tested
compounds). n = 5−6 animals per group.
TABLE 7 | The influence of the tested compounds on lipid peroxidation in
rat brain homogenate—antioxidant effect.
Compound Absorbance % reduction of absorbance
(% antioxidant activity)
HBK-14 0.939 ± 0.007 −4.10
HBK-15 0.891 ± 0.008 1.22
HBK-16 0.752 ± 0.007 16.63
HBK-17 0.773 ± 0.009 14.30
HBK-18 0.781 ± 0.004 13.41
HBK-19 0.698 ± 0.007 22.62
Carvedilol 0.094 ± 0.002 89.58
The rates of membrane lipid peroxidation were measured using rat brain homogenate by
the formation of thiobarbituric acid reactive substances (TBARs). The studied compounds
were tested at a concentration of 10−3 M. The TBARs were measured at 532 nm.
to cardiac arrhythmias. In our opinion, the lack of hypotensive
properties at antiarrhythmic doses makes HBK-19 the most
interesting compound in the studied group. Our results suggest
that the receptor profile of HBK 19 (the highest affinity for α1A
and the lowest for α1D) is the most beneficial in preventing
adrenaline-induced arrhythmia. Interestingly, this suggests that
in in vivo conditions the selectivity between α1A and α1D is
much more important in achieving the optimal profile of α1-
adrenolytics acting as antiarrhythmic agents, than the selectivity
between α1A and α1B.
In order to prove that hypotensive properties of tested
compounds were a result of their α1-adrenolytic properties,
we performed the experiments with methoxamine (selective
α1-adrenoceptor agonist). Drugs that selectively block α1-
adrenergic receptors significantly inhibit pressor response to
methoxamine. All studied compounds blocked the effect caused
by methoxamine, thus we concluded that their hypotensive
activity was due to α1-adrenolytic properties.
Oxidative stress plays an important role in arrhythmias
(Dudek et al., 2014; Sovari, 2016). Reactive oxygen species
(ROS) prolong action potential duration, induce early
afterdepolarizations, and delayed afterdepolarizations in rats
and guinea-pigs (Beresewicz and Horackova, 1991). Scientists
indicated that oxidative stress activated Ca2+/CaM-dependent
kinase II (CaMKII), and consequently caused arrhythmias
(Xie et al., 2009). Rabbits with cardiac hypertrophy pretreated
with CaMKII inhibitor were less likely to develop ventricular
arrhythmias (Ke et al., 2007). Kirshenbaum et al. (1990) showed
that vitamin E (antioxidant) protected rats with chronic heart
hypertrophy against adrenaline-induced arrhythmias. This
suggests that oxidative stress plays role in adrenaline-induced
arrhythmias.
Given the significant antiarrhythmic effect of the
studied compounds, we decided to investigate whether 2-
methoxyphenylpiperazine derivatives possess additional
antioxidant activity. Strong antioxidant activity might have
contributed to their antiarrhythmic effect. This would
explain their significant effect in adrenaline-induced model
of arrhythmia. Our experiments showed that among all studied
compounds only HBK-16, HBK-17, HBK-18, and HBK-19
weakly inhibited lipid peroxidation. The effect elicited by
HBK-19 was the strongest in the group. However, its activity
was around eight-fold weaker than the effect caused by
carvedilol. Although HBK-16, HBK-17, HBK-18, and HBK-19
possessed weaker antioxidant properties than carvedilol, they
showed stronger antiarrhythmic activity. This confirms that
in adrenaline-induced arrhythmia model, the blockade of
α1-adrenoceptors is more important for antiarrhythmic activity
than antioxidant properties of the compound. Moreover, our
findings suggest that antiarrhythmic properties of studied
compounds resulted predominantly from α1-adrenolytic
properties.
The levels of cardiac α1-adrenoceptor are around 10-fold
higher in rats than in humans. This may suggest that the
role of α1-adrenoceptor blockade in arrhythmia is not as
significant in humans. Interestingly, despite lower expression
of α1-adrenoceptors in human heart, scientists proved that
they play a significant role in arrhythmias (Furushima et al.,
2001). Kurtzwald-Josefson et al. (2014) identified a contribution
of α-adrenergic pathway to pathogenesis of catecholamine-
induced arrhythmia, and suggested α-blockade as an effective
therapy in the murine model of catecholaminergic polymorphic
ventricular tachycardia. The Authors suggested α-adrenolytics
as an alternative treatment in humans resistant to β-blockers.
Thus, it would be reasonable to keep searching for antiarrhythmic
agents among α1-adrenolytics.
Since structural similarity of studied compounds reduces
the likelihood of various mechanisms of action, in future
studies we plan to investigate another set of structurally similar
2-methoxyphenylpiperazine derivatives with higher selectivity
toward α1A-adrenoceptor subtype. This might give more insight
into the role of α1A-adrenoceptor subtype in antiarrhythmic
effect.
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In conclusion, the studied 2-methoxyphenylpiperazine
derivatives possessed high affinity for α1-adrenoceptors and
competitively antagonized α1A, α1B, and α1D receptor subtypes.
The compounds that possessed stronger α1A-adrenolytic
properties (i.e., HBK-16, HBK-17, HBK-18, and HBK-19)
were the most active compounds in adrenaline-induced
arrhythmia. We suggest that their antiarrhythmic activity results
predominantly from strong α1A-adrenolytic properties.
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